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A gene, causing a deﬁciency of the enzyme alpha-galactosidase A.
(1) The enzyme defect leads to progressive intracellular accumu-
lation of globotriaosylceramide in lysosomes of various tissues and
organs, including heart, kidney and nerve system. Cardiac
involvement is common and is presenting as concentric left ven-
tricular hypertrophy. Myocardial replacement ﬁbrosis is a typical
feature of more advanced stages of Fabry cardiomyopathy, ﬁrst
limited to the mid-myocardial layers of the basal postero-lateral
wall, then spreading to transmural ﬁbrosis. Since 2001, enzyme
replacement therapy is available. If therapy is started early, before
myocardial ﬁbrosis has developed, a long-term improvement of
myocardial morphology, function and exercise capacity can be
achieved. In end-stage cardiomyopathy enzyme replacement
therapy might prevent further progression of the disease. This
review provides an overview of Fabry disease, with a focus on
cardiac involvement with its characteristic features, clinical pre-
sentation and possible treatment.
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Anderson Fabry disease is a rare genetic lysosomal storage disorder with X-chromosomal inheri-
tance [1]. Reported incidence is about 1:40,000 worldwide [2]. However, due to underdiagnosed
atypical phenotypes and mutations with limited alpha-galactosidase A activity, the actual incidence is
likely to be much higher. The clinical signiﬁcance of these mutations, however, has not yet been
satisfactorily clariﬁed [3]. The disease is induced by amutation in the alpha-galactosidase A gene (GLA)
causing a deﬁciency of the hydrolase alpha-galactosidase A (alpha-GalA). Absent or reduced enzyme
activity leads to the inability to catabolize globotriaosylceramide (Gb3) and related glycosphingolipids,
with the result of a progressive intracellular storage of Gb3 in various tissues and organs and an
elevated plasma concentration of lyso-Gb3. The most commonly affected organs are heart, vascular
endothelium of the kidney, nervous system, eyes, and skin (Fig. 1) [4]. Cardiac manifestations including
arrhythmias, chronic heart failure and small vessel disease occur frequently. Of note, malignant ar-
rhythmias [5] are the predominant cause for the substantially increased morbidity and reduced life
expectancy [6]. Beside the classical variant of Fabry disease, an atypical variant is also known, char-
acterized by residual alpha-galactosidase A activity. In those cases the clinical manifestation starts later
in life, often with single organ involvement, as heart or kidney [7,8].
Anderson Fabry disease is one of the rare lysosomal storage disorders for which a cause-speciﬁc
therapy is available [9,10]. Enzyme replacement therapy (ERT) has been approved since 2001. Two
different enzyme preparations are available: agalsidase alfa and agalsidase beta. Clinical studies have
shown that enzyme replacement therapy (ERT) may slow or halt disease progression [9e12]. However,
the success of therapy appears to depend heavily on the stage of the disease [12].Pathophysiology
The malfunction of alpha-Gal A leads to a progressive accumulation of Gb3 in all body cells con-
taining lysosomes, including vascular endothelium and smooth muscle cells [13]. Intracellular accu-
mulation starts in utero and is probably the pathogenetic trigger event of the disease [14,15].
Although the clinical presentation of Fabry disease is well explored, the pathomechanism linking
the intracellular deposition of Gb3 to the potential cell and tissue dysfunction and ﬁnally to the clinical
manifestations is still not sufﬁciently clariﬁed [4]. It has been shown that the storage of Gb3 induces an
excessive production of reactive oxygen species in cultured vascular endothelial cells thereby
increasing oxidative stress. Gb3 also up-regulates the expression of adherence molecules in vascular
endothelium [16]. Other data indicate that Gb3 may cause the release of pro-inﬂammatory cytokines,
especially dendritic cells and monocytes [4]. Thus, it can be hypothesized that Gb3 storage triggers a
cascade of pathophysiological processes leading to a structural cellular change, tissue defects, and e
over time e to organ failure.
Furthermore, globotriaosylsphingosine (lyso-Gb3), a deacylatedmetabolite of Gb3, appears to be an
additional factor in the pathogenesis of Fabry disease. Lyso-Gb3 is an inhibitor of the enzyme alpha-
galactosidase A, thus promoting the storage of Gb3 as well as it stimulates the proliferation ofFig. 1. Overview of the typical organs involved in Fabry disease. The dark ﬁelds represent the most important involved organs. Other
organs with less effect on life expectancy are marked by a more light-colored circle.
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in the plasma of male and female Fabry patients is sphingosine-1-phosphate (S1P). It has been shown,
that in-vitro S1P induces hypertrophy of the cardiomyocytes. In vivo the plasma level of S1P correlated
strongly with the mass of left ventricular (LV) hypertrophy. Altogether it seems that S1P contributes a
lot in the development of cardiovascular remodeling due to its proliferative mechanism [19].
Clinical presentation
In hemizygous males, the clinical manifestation of Fabry disease shows characteristic symptoms
during childhood and adolescence, such as angiokeratoma, hypohydrosis, acroparesthesia, pain crises
and gastrointestinal symptoms like diarrhea. In adulthood, progressive Gb3 accumulation in the
microvasculature causes ischemic damages especially affecting the kidney, brain and heart, which may
cause symptoms related to renal failure, stroke and cardiovascular diseases [18,20,21]. Heterozygous
females were thought to be asymptomatic carriers. However, it is now well acknowledged that het-
erozygous females can also be affected and may develop the full phenotype of disease manifestation,
even though the aggravation of the disease occurs later in life [5,18,22].
Cardiac involvement is frequent in Fabry patients and is one of the most important causes for
reduced life expectancy and disease-related death [6]. Various cardiac manifestations, including
symptoms of heart failure, angina pectoris and arrhythmias have been reported [7,8,23,24].
The above mentioned atypical “cardiac variant” of the disease presents with limited clinical
manifestation. These patients are middle-aged and present with so hitherto unexplained hypertrophy
of the LV. The enzyme test reveals residual alpha-galactosidase A activity, andmost of the patients have
less symptoms when compared to classical Fabry patients [7,8].
The Fabry cardiomyopathy
More than 50% of all Fabry patients have a cardiac involvement (ie, Fabry cardiomyopathy), most
frequently concentric left ventricular hypertrophy (LVH) [6,18,23]. The intracellular accumulation of
Gb3 also occurs within myocytes, valves and vascular endothelium of the heart [9,25]. Histologically,
the Fabry cardiomyopathy is characterized bymyocyte hypertrophy and vacuolation [26]. However, the
storage of Gb3 alone is insufﬁcient to explain the full extent of myocardial abnormalities seen in Fabry
patients. In addition, the interstitial remodeling appears to be an important feature of Fabry cardio-
myopathy [25]. The reason is probably a combination of intracellular lysosomal storage of Gb-3, an
increase of trophic factor such as lyso-Gb3, and a neurohormonal activation in the plasma that induces
hypertrophic activation and interstitial remodeling [18,25e28].
In most Fabry patients with a cardiomyopathy a concentric left ventricular hypertrophy with an
end-diastolic wall thickness of up to 16 mm can be found. This ventricular hypertrophy increases with
disease progression. The typical pattern is a concentric thickening without LV outﬂow tract obstruc-
tion. In these patients LV systolic function, measured by ejection fraction, is normal. This distinguishes
Fabry cardiomyopathy from idiopathic hypertrophic cardiomyopathy (HCM) and can be used to screen
Fabry patients among individuals with unexplained LV hypertrophy [29]. Other typical ﬁndings in
Fabry cardiomyopathy are prominent papillary muscles [24,30] and a preserved global ejection fraction
combined with early stages of diastolic dysfunction [6,31]. Using strain rate imaging based on tissue
Doppler imaging it could be shown that regional myocardial function is impaired. Those abnormalities
seem to affect mainly longitudinal contraction and start in the basal segment of the postero-lateral wall
of the LV. In more advanced stages of the disease, both regional longitudinal and radial function pa-
rameters are reduced [11,12,23,31].
The end-stage Fabrycardiomyopathy is characterizedby intramural replacementﬁbrosis also limited to
the basal postero-lateral wall of the LV [24,25]. The non-invasive gold-standard to detect myocardial
ﬁbrosis is late gadolinium-enhancedmagnetic resonance imaging (MRI) [25]. An indirectway to screen for
regional myocardial ﬁbrosis is functional strain rate imaging by echocardiography [32,33]. Histologically,
theﬁbrotic changes begin in themid-myocardial layers and sprawlwith disease progression to transmural
ﬁbrosis, accompaniedby thinningof thesesegments. Functionally, thepresenceofmyocardial replacement
ﬁbrosis leads towallmotion abnormalitieswith lower regional systolic deformation values [23,33,34]. The
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lignant ventricular arrhythmias [12], both leading to a poor prognosis for Fabry patients [23,34,35].
Another regularly reported phenomenon of the cardiomyopathy includes valve abnormalities. In
general, hemodynamic signiﬁcant valve abnormalities are rare ﬁndings with little clinical impact
[24,36]. Only few Fabry patients exhibited mild or moderate aortic, mitral and tricuspid insufﬁciency,
especially in end-stage cardiomyopathy [24].
Echocardiography
The most common tool to screen for Fabry cardiomyopathy is echocardiography, which is widely
available and easily applicable. Especially for patients with contraindications against MRI, for example
patients with implanted cardio deﬁbrillator or pacemaker or patients with end-stage renal disease,
echocardiography is the only diagnostic possibility to detect myocardial function andmorphology [33].
For those patients the echocardiography is essential for diagnosis and therapy monitoring [37].
Echocardiography can be used to detect early stages of the disease mainly characterized by a
concentric non-obstructive left ventricular hypertrophy and, in more advanced stages, by an asym-
metrical hypertrophy presenting with a grossly thickened septum and less hypertrophy of the
posterolateral wall. Other ﬁndings include the prominent papillary muscles as mentioned above
(Fig. 2). Echocardiography is also the method of choice to monitor treatment effects.
There are two echocardiographic techniques to assess indirectly replacement ﬁbrosis: strain rate
imaging and speckle tracking. Ultrasonic strain-rate imaging is based on speciﬁc visual features,
consisting of a “double peak sign” with two clearly identiﬁable peaks: i) a sharp ﬁrst peak in early
systole, followed by a rapid fall in strain rate close to zero; and ii) a second strain rate peak during the
isovolumetric relaxation period. These indicators can be used to evaluate the quality, but not the
quantity of the regional ﬁbrosis in hypertrophic myocardium [32]. This method is highly reliable,
especially in detecting sub-clinical involvement [7,32]. However, it is technically demanding, time
consuming, and difﬁcult for post processing and therefore restricted to specialized centers [32].
In contrast, 2D speckle-tracking, a relatively new imaging technique used to detect LE related
functional abnormalities, is widely available, highly reproducible, and simple to implement [38]. With
this technique the lower deformation values associated with the presence of myocardial replacement
ﬁbrosis can be assessed. Thus, low systolic longitudinal strain values in the basal postero and lateral LV
segments indicate myocardial ﬁbrosis [33]. The method does not allow an exact quantiﬁcation of the
amount of ﬁbrosis. However, it has been shown that a systolic longitudinal strain value of more thanFig. 2. Typical echocardiography image. Typical echocardiographic image of a patient with Fabry cardiomyopathy. This apical four-
chamber view is showing a prominent papillary muscle as well as a thickened interventricular septum and lateral wall of left
ventricle.
Fig. 3. Typical magnetic resonance tomography image. Magnet resonance imaging of the left ventricle from a patient with severe
ﬁbrosis. This short axis view is illustrating an area in the posterolateral wall with a signiﬁcant amount of late enhancement
(¼ﬁbrosis) indicated by the red arrows.
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value lower than 12.5% is related strong indicator of replacement ﬁbrosis [33].
Magnetic resonance tomography
Besides the useful technique of echocardiography, cardiac MRI is especially important to screen for
myocardial replacement ﬁbrosis by gadolinium late enhancement imaging (Fig. 3). In areas with
myocardial ﬁbrosis, the intercellular space is increased. Chelated gadolinium then diffuses into this
space and is unable to cross the cell membrane. The distribution kinetic is therefore slower, and a
higher relative concentration of gadolinium is found in myocardial areas with ﬁbrosis compared to
unaffected myocardium [7,25].
The assessment of myocardial ﬁbrosis is essential to stage the cardiomyopathy and is necessary for
monitoring therapy effects [23,36]. Consequently, every adult Fabry patient should receive a cardiac
MRI scan once a year if possible. This is particularly important for female patients, who often develop
myocardial ﬁbrosis in the postero-lateral wall despite otherwise non-hypertrophic myocardium. Thus,
in female Fabry patientsMRI with late enhancement imaging is the only possibility to detect a potential
cardiomyopathy [39].
Electrocardiography
The end-stage cardiomyopathy is characterized by the co-existence of LVH, regional myocardial
thinning and the presence of wall motion abnormalities in the ﬁbrotic segment [23,34,40]. In this case
characteristic changes seen on resting ECG are a positive Sokolow-Lyon index and a negative T-wave in
the precordial leads (Fig. 4).
Affected hearts are vulnerable to develop cardiac arrhythmias, including sinus bradycardia, bra-
dyarrhythmias and malignant ventricular arrhythmias [35]. Therefore, patients should be regularly
screened for cardiac arrhythmias by 24-h Holter-ECG. In patients with typical symptoms like dizziness
or syncopewith inconspicuous 24-hHolter-ECG, the implantation of a cardiac event recorder should be
Fig. 4. Typical electrocardiographic image. Electrocardiography from a male Fabry patient with advanced Fabry cardiomyopathy.
Note the positive Sokolow-Lyon index as a marker for left ventricular hypertrophy as well as the T-wave inversion in V4eV6.
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elegantly identifying potentially life-threatening arrhythmias.Biomarkers
Two biomarkers, Gb3 and lyso-Gb3, may be used as diagnostic tools or as screening parameter for
high-risk patients [40e42]. The concentration of Gb3 can best be measured in the sediment of urine.
It is elevated in all hemizygous patients with the classic or the renal variant of the disease and is
therefore a reliable, non-invasive, simple tool to screen for Fabry disease. However it is not an ideal
biomarker to monitor therapy effects and also does not detect patients with the cardiac variant
[43,44].
The most important biomarker is lyso-Gb3, a degradation product of the accumulated Gb3. It
has been shown that plasma lyso-Gb3 concentration is severely elevated in all classical Fabry
patients. In addition, it is slightly elevated in atypical late onset mutations. Overall, the level of
lyso-Gb3 is considered to predict the potential severity of unknown mutations. This is particularly
helpful to detect atypical late onset forms and women with alpha-GalA activity around the normal
threshold [3,45]. Additionally, lyso-Gb3 is viewed as an independent risk indicator for white
matter lesions in the brain in male patients and for left ventricular hypertrophy in female patients
[17].
Therapy of the Fabry cardiomyopathy
Enzyme replacement therapy
Enzyme replacement therapy allows a causal treatment of Fabry disease. Intravenous infusion
with recombinant alpha-galactosidase A replaces the missing enzyme and catabolizes the lipid
deposits [9,10]. The ERT infusion has to be given intravenously every two weeks throughout life.
Therefore, it is essential to carefully establish the diagnosis and deﬁne the indication for ERT. ERT
aims at maintaining organ function and/or improving organ dysfunctions. So far, this therapy is
the only way to stabilize the progression of the disease [22]. There are two different kinds of
enzyme-products available: agalsidase alfa and agalsidase beta. In respect to cardiac function and
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so far [46].
Initial biopsy studies demonstrated that ERT effectively clears microvascular endothelial deposits of
Gb-3 from the kidney, the skin and the heart of most Fabry patients [9,10,47,48]. This may then induce a
decrease of LV mass, enhance regional myocardial function [11,12,49], and improve exercise capacity
[12] as well as health-related quality of life [50].
Before starting ERT, a precise staging of disease status or progression is necessary. The therapeutic
success of ERT on Fabry cardiomyopathy depends highly on the extent of myocardial ﬁbrosis at
baseline. Of note, patients with proven myocardial ﬁbrosis may have only limited or no beneﬁt from
ERT. By contrast, the greatest effect of therapy may be achievable before myocardial ﬁbrosis has
developed [12,51,52]. In these cases, a decrease of myocardial mass, improvement of regional
myocardial function or an increase in exercise capacity can be accomplished [12]. Thus, a regularly
monitoring of heart morphology and function in all Fabry patients is necessary and an early start of ERT
is desirable [12,51].
It has to be considered that almost all patients develop anti-agalsidase antibodies with neutralizing
activity during long-term ERT. This affects predominantly male patients without any alpha-Gal A-ac-
tivity. Nevertheless, female patients may also develop antibodies despite substantial levels of residual
enzyme activity [53]. However, the impact of these antibodies on the effectiveness of treatment is still
unknown (see chapter 5).
Additional therapy for the heart
Fabry patients, especially in more advanced stages of the disease, beneﬁt markedly from a
comprehensive clinical management including ERT but also concomitant medical treatment. First
choice is the use of angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blockers.
From other forms of myocardial hypertrophy, it is known that ACEi have positive effects on the
regression of the hypertrophy [54,55]. Furthermore, ACEi reduce proteinuria and stabilize kidney
function [56]. However, it is to be noted that hypotension may become a therapy-limiting side effect.
Therefore, regular blood pressure monitoring after initiation of ACEi therapy is advised.
In addition, the use of b-adrenergic blocking can be necessary in order to treat tachycardic ar-
rhythmias and to prevent ventricular arrhythmias [57]. Since many Fabry patients develop bradycar-
dias [35], a 24-h Holter ECG should be conducted before and during therapy, especially if symptoms
like dizziness or syncope are reported. If relevant bradycardia is conﬁrmed, a pacemaker implantation
should be considered [35].
Fabry patients with end-stage cardiomyopathy developing malignant ventricular arrhythmias
should be evaluated for the implantation of a cardio-deﬁbrillator (ICD) [23,57,58]. A combination of ERT
with antiarrhythmic therapy as amiodarone should be avoided, because an interaction between
amiodarone and ERT has been described [59].
In case of atrial ﬁbrillation, a restoration to sinus rhythm should be discussed to avoid the risk of
bradycardia, which leads to reduced exercise capacity. If a restoration to sinus rhythm is not possible,
oral anticoagulation is indicated.
Conclusions
Fabry cardiomyopathy is a clinically important organ manifestation of Fabry disease. Its detection is
frequently difﬁcult, requiring a comprehensive cardiac diagnostic approach. As a consequence, all
patients should need to be re-examined annually by a Fabry specialist, regardless whether ERT is
indicated. Cardiac diagnostics need to focus on myocardial ﬁbrosis, because its well-recognized impact
on prognosis. A cardiologist together with the other involved disciplines should deﬁne the indication
for ERT. Before and during ERT it is important to initiate additional therapy in almost every Fabry
patient.
During the past 10 years, many new aspects of the Fabry cardiomyopathy have been investigated. In
particular, knowledge on the clinical presentation of patients with Fabry cardiomyopathy has
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ology and thus, improved therapy. For clinical research, Fabry centers should closely cooperate in
network structures that facilitate the conduct of appropriately powered clinical trials.Conﬂict of interest
The following authors have received speaker's honoraria from Genzyme and Shire: Frank Weide-
mann, Christoph Wanner.
All authors had access to the data and a role in writing the manuscript.Practice points
 Echocardiography is essential for diagnosis and therapy monitoring
 Especially for female patients MRI with late enhancement imaging is sometimes the only
possibility to detect potential myocardial fibrosis and thus the cardiomyopathy
 If therapy is started early, before myocardial fibrosis has developed, a long-term improve-
ment of myocardial morphology, function and exercise capacity can be achieved
 Patients in more advanced stages benefit highly of a comprehensive management including
ERT and concomitant medical treatment
Research agenda
 Basic and clinical research for better understanding of the pathophysiology of Fabry Car-
diomyopathy is necessary
 Investigations about new diagnostic tools like biomarkers to detect early stages of Fabry
Cardiomyopathy should be done
 Trials to define the initiation and indication for ERT and the effect of ERT on the heart are
needed
 The influence of anti-agalsidase antibodies on the effectiveness of treatment should be
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